RBC Nudges Vertex Pharmaceuticals Price Target Higher Amid Biotech Outlook Update

RBC Capital Markets has increased its price target for Vertex Pharmaceuticals (VRTX) as it updates its outlook for the biotech sector. This reflects a positive analyst sentiment towards the company.